4-fluoro-3-[(4-hydroxy-1-piperidyl)sulfonyl]-N-(3,4,5-trifluorophenyl)benzamide

ID: ALA4533071

Cas Number: 1445790-55-5

PubChem CID: 89663273

Product Number: N413621, Order Now?

Max Phase: Preclinical

Molecular Formula: C18H16F4N2O4S

Molecular Weight: 432.40

Molecule Type: Unknown

Associated Items:

This product is currently unavailable

Names and Identifiers

Canonical SMILES:  O=C(Nc1cc(F)c(F)c(F)c1)c1ccc(F)c(S(=O)(=O)N2CCC(O)CC2)c1

Standard InChI:  InChI=1S/C18H16F4N2O4S/c19-13-2-1-10(18(26)23-11-8-14(20)17(22)15(21)9-11)7-16(13)29(27,28)24-5-3-12(25)4-6-24/h1-2,7-9,12,25H,3-6H2,(H,23,26)

Standard InChI Key:  KKMFSVNFPUPGCA-UHFFFAOYSA-N

Molfile:  

 
     RDKit          2D

 29 31  0  0  0  0  0  0  0  0999 V2000
    7.3300  -18.1350    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    6.5128  -18.1350    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
    6.9214  -18.8428    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    2.9743  -13.6487    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.9732  -14.4682    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.6812  -14.8772    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.3909  -14.4678    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.3880  -13.6451    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.6794  -13.2398    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.0992  -14.8753    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    5.1005  -15.6924    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.8089  -16.0999    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.3934  -16.1022    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    5.8055  -16.9145    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.5131  -17.3219    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.2211  -16.9121    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.2172  -16.0907    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.5091  -15.6870    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.2665  -13.2403    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    7.9300  -17.3186    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    5.8067  -18.5484    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    5.0962  -18.1421    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.3922  -18.5520    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.3930  -19.3706    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.1039  -19.7775    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.8140  -19.3660    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.6862  -19.7808    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    2.2651  -14.8763    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    3.6770  -12.4227    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
  2  1  2  0
  3  2  2  0
  4  5  2  0
  5  6  1  0
  6  7  2  0
  7  8  1  0
  8  9  2  0
  9  4  1  0
  7 10  1  0
 10 11  1  0
 11 12  1  0
 11 13  2  0
 12 14  2  0
 14 15  1  0
 15 16  2  0
 16 17  1  0
 17 18  2  0
 18 12  1  0
  4 19  1  0
 16 20  1  0
 15  2  1  0
  2 21  1  0
 21 22  1  0
 21 26  1  0
 22 23  1  0
 23 24  1  0
 24 25  1  0
 25 26  1  0
 24 27  1  0
  5 28  1  0
  9 29  1  0
M  END

Alternative Forms

  1. Parent:

    ALA4533071

    NVR 3-778

Associated Targets(Human)

HepG2 2.2.15 (869 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Hepatitis B virus (7925 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
HBcAg Core antigen (581 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 432.40Molecular Weight (Monoisotopic): 432.0767AlogP: 2.64#Rotatable Bonds: 4
Polar Surface Area: 86.71Molecular Species: NEUTRALHBA: 4HBD: 2
#RO5 Violations: HBA (Lipinski): 6HBD (Lipinski): 2#RO5 Violations (Lipinski):
CX Acidic pKa: 12.95CX Basic pKa: CX LogP: 2.01CX LogD: 2.01
Aromatic Rings: 2Heavy Atoms: 29QED Weighted: 0.57Np Likeness Score: -1.92

References

1. Na HG, Imran A, Kim K, Han HS, Lee YJ, Kim MJ, Yun CS, Jung YS, Lee JY, Han SB..  (2020)  Discovery of a New Sulfonamide Hepatitis B Capsid Assembly Modulator.,  11  (2): [PMID:32071684] [10.1021/acsmedchemlett.9b00550]
2. Kuduk SD, Lam AM, Espiritu C, Vogel R, Lau V, Klumpp K, Flores OA, Hartman GD..  (2019)  SAR studies in the sulfonyl carboxamide class of HBV capsid assembly modulators.,  29  (16): [PMID:31227344] [10.1016/j.bmcl.2019.05.029]
3. Lv K, Li W, Wu S, Geng Y, Wang A, Yang L, Huang M, Chowdhury K, Li Y, Liu M..  (2020)  Amino acid prodrugs of NVR3-778: Design, synthesis and anti-HBV activity.,  30  (9): [PMID:32173194] [10.1016/j.bmcl.2020.127103]
4. Lee YH,Cha HM,Hwang JY,Park SY,Vishakantegowda AG,Imran A,Lee JY,Yi YS,Jun S,Kim GH,Kang HJ,Chung SJ,Kim M,Kim H,Han SB.  (2021)  Sulfamoylbenzamide-based Capsid Assembly Modulators for Selective Inhibition of Hepatitis B Viral Replication.,  12  (2.0): [PMID:33603970] [10.1021/acsmedchemlett.0c00606]
5. Kuduk SD,Stoops B,Alexander R,Lam AM,Espiritu C,Vogel R,Lau V,Klumpp K,Flores OA,Hartman GD.  (2021)  Identification of a new class of HBV capsid assembly modulator.,  39  [PMID:33610748] [10.1016/j.bmcl.2021.127848]
6. Li X, Zhang Z, Chen Y, Wang B, Yang G, Xu X, Yechao B, Bai D, Feng B, Mao Y, Feng J, Bai C, He F, Tao W..  (2022)  Discovery of SHR5133, a Highly Potent and Novel HBV Capsid Assembly Modulator.,  13  (3.0): [PMID:35300087] [10.1021/acsmedchemlett.2c00002]
7. Cole AG, Kultgen SG, Mani N, Ardzinski A, Fan KY, Thi EP, Dorsey BD, Stever K, Chiu T, Tang S, Daly O, Phelps JR, Harasym T, Olland A, Suto RK, Sofia MJ..  (2022)  The identification of highly efficacious functionalised tetrahydrocyclopenta[c]pyrroles as inhibitors of HBV viral replication through modulation of HBV capsid assembly.,  13  (3.0): [PMID:35434625] [10.1039/d1md00318f]
8. Ivanova Bencheva L, Donnici L, Ferrante L, Prandi A, Sinisi R, De Matteo M, Randazzo P, Conti M, Di Lucia P, Bono E, Giustini L, Vittoria Orsale M, Patsilinakos A, Monteagudo E, Iannacone M, Summa V, Guidotti LG, De Francesco R, Di Fabio R..  (2022)  Discovery and antiviral profile of new sulfamoylbenzamide derivatives as HBV capsid assembly modulators.,  73  [PMID:35868496] [10.1016/j.bmcl.2022.128904]
9. Ren Y, Ma Y, Cherukupalli S, Tavis JE, Menéndez-Arias L, Liu X, Zhan P..  (2020)  Discovery and optimization of benzenesulfonamides-based hepatitis B virus capsid modulators via contemporary medicinal chemistry strategies.,  206  [PMID:32949990] [10.1016/j.ejmech.2020.112714]

Source